NLRP3 and Parkinson disease: Taken together, these studies indicate that inhibition of the NLRP3 inflammasome/ASC speck at various stages of its pathway (inhibiting inflammasome assembly, its downstream inflammatory signaling components, or the ASC speck’s interaction with other proteins) has potential to reduce or prevent disease progression in AD and PD.